BCDA BioCardia Inc. Forecast, Technical & Fundamental Analysis
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs... Show more
BCDA is expected to report earnings to rise 118.75% to -17 cents per share on August 12
Q2'26
Est.
$-0.17
Q2'24
Beat
by $0.12
Q1'24
Beat
by $0.11
Q4'23
Beat
by $0.02
Q3'23
Beat
by $0.02
The last earnings report on August 13 showed earnings per share of -7 cents, beating the estimate of -20 cents. With 112.35K shares outstanding, the current market capitalization sits at 14.39M.
A.I. Advisor
published General Information
General Information
a clinical-stage regenerative medicine company, which develops novel therapeutics for cardiovascular diseases
A.I.dvisor indicates that over the last year, BCDA has been closely correlated with SMMT. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BCDA jumps, then SMMT could also see price increases.
BCDA's RSI Oscillator recovers from oversold territory
The RSI Oscillator for BCDA moved out of oversold territory on May 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where BCDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BCDA just turned positive on June 16, 2026. Looking at past instances where BCDA's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BCDA advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .
BCDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCDA as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BCDA entered a downward trend on May 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BCDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.346) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). BCDA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). BCDA's P/S Ratio (2000.000) is slightly higher than the industry average of (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
